
|Articles|July 4, 2020
- June 2020
- Volume 3
- Issue 2
Hereditary Angioedema: Management Updates for the Specialty Pharmacist
This continuing education activity is supported by an educational grant from Takeda.
Advertisement
THIS ACTIVITY IS SUPPORTED BY AN EDUCATIONAL GRANT FROM TAKEDA.
FACULTY
Melanie B. Radi, PharmD, CSP
Manager, Clinical Programs Specialty Clinical Services
AllianceRx Walgreens Prime
Pittsburgh, Pennsylvania
At the completion of this activity, the participant will be able to:
- Characterize the diagnosis and background of hereditary angioedema (HAE) and the significance of early intervention
- Examine the clinical data of FDA-approved agents and emerging therapies for acute treatment and prophylaxis of HAE
- Explore the need for individualized treatment and the role of the specialty pharmacist in patient education for effective HAE management
TARGET AUDIENCE: Pharmacists
ACTIVITY TYPE: Application
RELEASE DATE: May 15, 2020
EXPIRATION DATE: May 15, 2021
ESTIMATED TIME TO COMPLETE ACTIVITY: 2.0 hours
FEE: This lesson is offered for free at
Articles in this issue
over 6 years ago
CIDP Care: A Patient and Clinical Experts Weigh Inover 6 years ago
The Multidisciplinary Team Improves Cystic Fibrosis OutcomesAdvertisement
Related to this article

Pharmacists can use medication therapy management to screen for diabetes, educate patients about medication adherence and lifestyle modifications, and support early action.

Higher doses of injectable semaglutide have been shown to cause greater weight loss than standard doses with a similar safety profile.

In every practice setting, pharmacists can meet vaccine hesitancy with evidence, effective communication, and vetted resources that move patients toward “yes.”

Retail pharmacists use a quick checklist to spot risky antithrombotic duplicates, dosing mistakes, OTC interactions, and adherence gaps—helping prevent stroke and bleeding.

Health-system pharmacists confirm therapy matches stroke mechanism, screen for bleeding risk and drug interactions, and help patients transition to outpatient care.

Peer Reviewed
Identifying and screening Medicare Part D patients who are ordered brand-name cardiovascular medications for PACE/PACENET eligibility before discharge can reduce patients’ out-of-pocket costs for these medications.
Advertisement
Advertisement
Trending on Pharmacy Times
1
mRNA-1283 Associated With Lower Risk of Medically Attended COVID-19 Than BNT162b2 in Older Veterans
2
Survodutide for Obesity and CV Risk: Liver, Lipids, and Beyond
3
What Pharmacists Should Know About Transitioning Patients to Buprenorphine
4
Long-Acting HIV Injectables in Viremia and New Tenofovir-Free Oral Options
5


